Clinical Trial Update: A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for an autologous oxidized tumor cell lysate vaccine in recurrent ovarian/fallopian tube/primary peritoneal cancer; trial terminated with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Autologous oxidized tumor cell lysate vaccine (autologous oxidized tumor cell lysate vaccine)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-11-15